iGii
iGii has agreed a multi-million-pound deal with health monitoring company Prymexa to develop a toolkit that detects signs of perimenopause – the transition phase period before menopause that can start as early as the mid-30s.
With 60% of women under 40 not feeling informed about perimenopause or menopause, many experience a range of symptoms and increased risks of depression, osteoporosis and cardiovascular disease without guidance on managing these. A lack of awareness and monitoring can lead to misdiagnosis and missed opportunities for early intervention. Early identification of perimenopause allows for more personalised advice, treatment and support from medical professionals.
The toolkit will look at various monitoring options, including wearable devices and sensors, to enable simple and affordable at-home monitoring that can be closely tracked by a medical professional.
Integral to the technology is iGii’s sustainable carbon nanomaterial Gii, which the company says provides a low-cost, eco-friendly, and highly sensitive alternative to traditional carbon and metal-based sensors, making it effective for accurate assessment of menopause symptoms.
Sara Pardoe, Chief Executive Officer, Prymexa said: “Menopause receives a fraction of the investment compared to other medical fields, yet half the population will experience it and demand for effective management solutions is growing exponentially. Our research aims to bring individuals closer to a simple, clear understanding of their menopause journey and how to best manage it.”
Jean-Christophe Granier, CEO, iGii said: “Gii has the potential to significantly improve point-of-care human diagnostics and make accurate, quick medical results the norm. Its properties provide a more affordable, sustainable, scalable and sensitive sensing platform for high-quality results in labs and at home. This project with Prymexa highlights the real value and potential of Gii and we look forward to working with them to positively impact the lives of those going through the perimenopause period.”
David Atkinson, Founder of Prymexa added: “We are thrilled about this partnership, which promises to transform lives through our extensive research and development efforts. By joining forces with iGii, we can enhance the precision and sensitivity of our toolkit, accelerating our product development and ultimately making a significant difference in people’s lives.”
Romy Williams and Sophie Stubbs, Directors at Prymexa said: “Prymexa is continuously advancing and solidifying its position in the health monitoring industry. Our partnership with iGii further underscores our commitment to easing the perimenopausal and menopausal journey for individuals. By collaborating, we are enhancing our ability to offer comprehensive, supportive solutions tailored to the unique needs of those experiencing these significant life transitions. We are both thrilled about the incredible benefits our solutions will bring in the coming years.”
